Related Experiment Videos
Ropinirole therapy for Parkinson's disease
Rajesh Pahwa1, Kelly E Lyons, Robert A Hauser
1Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd, Kansas City, KS 66160, USA. rpahwa@kumc.edu
Expert Review of Neurotherapeutics
|April 28, 2005
Summary
Ropinirole effectively treats Parkinson's disease by managing symptoms and motor fluctuations. Early use may reduce dyskinesias, and a new formulation promises improved convenience and efficacy.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Ropinirole is a nonergoline dopamine D2 agonist.
- It is indicated for early and advanced Parkinson's disease.
Purpose of the Study:
- To evaluate ropinirole's efficacy in Parkinson's disease.
- To assess its impact on motor fluctuations and dyskinesias.
- To explore potential neuroprotective effects.
Main Methods:
- Clinical trials comparing ropinirole monotherapy vs. levodopa.
- Studies assessing ropinirole as an adjunct to levodopa.
- Positron emission tomography imaging to assess neuronal loss.
Main Results:
- Ropinirole improves signs and symptoms in early Parkinson's disease.
- It reduces 'off' time and allows levodopa dose reduction in advanced stages.
- Initial ropinirole use may lead to fewer dyskinesias compared to levodopa alone.
Conclusions:
- Ropinirole is a valuable treatment for Parkinson's disease.
- It offers benefits in both early and advanced stages.
- Further research is needed to confirm potential neuroprotective effects and evaluate a new once-daily formulation.